|
GSK PLC - London-based pharmaceutical firm formerly known as GlaxoSmithKline - Notes ViiV Healthcare Ltd received marketing approval by Japan's Ministry of Health, Labour, & and Welfare for Vocabria used in combination with Rekambys and Edurant.
Vocabria, Rekambys and Edurant are treatments for HIV inflections.
ViiV is a pharmaceutical company specializing in the development of therapies for HIV. It was launched as a joint venture by Pfizer Inc and GSK in 2009. GSK holds an 85% stake in ViiV and Pfizer holds 15%.
Current stock price: 1,729.00 pence
12-month change: down 29%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
